IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Bought by E Fund Management Hong Kong Co. Ltd.

E Fund Management Hong Kong Co. Ltd. grew its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 182.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 164 shares of the company’s stock after purchasing an additional 106 shares during the period. E Fund Management Hong Kong Co. Ltd.’s holdings in IDEXX Laboratories were worth $68,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the company. Public Sector Pension Investment Board grew its stake in IDEXX Laboratories by 67.6% during the second quarter. Public Sector Pension Investment Board now owns 3,078 shares of the company’s stock worth $1,500,000 after buying an additional 1,241 shares during the period. Marshall Wace LLP raised its stake in shares of IDEXX Laboratories by 2.5% in the 2nd quarter. Marshall Wace LLP now owns 20,500 shares of the company’s stock valued at $9,988,000 after acquiring an additional 500 shares during the period. Daymark Wealth Partners LLC lifted its holdings in shares of IDEXX Laboratories by 37.1% during the 2nd quarter. Daymark Wealth Partners LLC now owns 621 shares of the company’s stock valued at $303,000 after acquiring an additional 168 shares in the last quarter. MBB Public Markets I LLC purchased a new stake in IDEXX Laboratories during the 2nd quarter worth $2,931,000. Finally, The Manufacturers Life Insurance Company increased its holdings in IDEXX Laboratories by 10.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 94,191 shares of the company’s stock valued at $45,890,000 after purchasing an additional 8,551 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

IDXX opened at $435.33 on Monday. The company has a market capitalization of $35.65 billion, a P/E ratio of 41.98, a PEG ratio of 3.63 and a beta of 1.36. The company has a 50-day moving average of $423.74 and a 200-day moving average of $456.20. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Thursday, October 31st. The company reported $2.80 EPS for the quarter, topping analysts’ consensus estimates of $2.69 by $0.11. The firm had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The firm’s revenue was up 6.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.53 earnings per share. Equities analysts expect that IDEXX Laboratories, Inc. will post 10.44 EPS for the current fiscal year.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the firm’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the sale, the director now directly owns 905 shares in the company, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 2.11% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research firms have recently issued reports on IDXX. Piper Sandler reiterated a “neutral” rating and issued a $435.00 target price (down previously from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Leerink Partners initiated coverage on shares of IDEXX Laboratories in a research report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price objective for the company. StockNews.com raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday, November 28th. JPMorgan Chase & Co. decreased their target price on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. Finally, Stifel Nicolaus cut their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a report on Thursday, October 10th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $523.86.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.